RESI AVAILABLE COPY

DO/ EO WORKSHEET cia Booker Paralegal/ National Stage U.S. Appl. No. International Appl. No. pplication tiled by: 20 months 2 30 months WIPO PUBLICATION INFORMATION: Publication Date: Not Published: Q U.S. only designated Q EP request Published : D EP request INTERNATIONAL APPLICATION PAPERS IN THE APPLICATION FILE: Q International Application (RECORD COPY) PCT/IB/331 Article 19 Amendments Request form PCT/RO/101 PCT/IPEA/409 IPER: Q EP Q JP Q SE Q AU PCT/ISA/210 - Search Report : □ EP □ JP □ SE □ AU US OFR OCH OES ORU OAT OKR O\_ US OFR OCH OES ORU OAT OKR OTHER \_\_\_ PCT/IPEA/409 IPER was NOT AVAILABLE at the time of ☐ NONE paralegal review Annexes to 409 Search Report References M Priority Document (s) No. RECEIPTS FROM THE APPLICANT (other than checked above): Basic National Fee (or authorization to charge) Preliminary Amendment(s) Filed on: \_ 2. \_\_\_\_\_ Information Disclosure Statement(s) Filed on: 2. Assignment Document (forwarded to Drawing Figure(s) - (# of drwgs. Assignment Branch) Translation of Article 19 Amendments Assignee PG Publication Notice ☐ entered not entered : Substitute Specification Filed on: not a page for page substitution replaced by Article 34 Amendment Annexes to 409 Verified Small Status Statement antered anot entered: Oath/ Declaration (executed) not a page for page substitution O no translation O other : \_ **DNA Diskette** Sequence Listing **Application Data Sheet** Power of Attorney/ Change of Address Other: ☐ I.A. used as Specification 35 U.S.C. 371 - Receipt of Request (PTO-1390) Date Acceptable Oath/ Declaration Received Date of Completion of requirements under 35 U.S.C. 371 Date of Completion of ALL requirements Date of Completion of DO/ EO 903 - Notification of Acceptance Date of Completion of DO/ EO 905 - Notification of Missing Requirements

Date of Completion of DO/ EO 909 - Notification of Abandonment Date of Completion of BO/EO 916 - Notification of Defective Response

Date of Completion of DO/ EO 923

Date of Completion of DO/ EO 922 - Notification to Comply w/ Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures